Insulin action enhancers for the management of Type 2 diabetes mellitus

Bibliography

• MARKS L: Counting the Cost: The Real Impact of Non-Insulin Dependent Diabetes. British Diabetic Association, King's Fund Policy Institute, London (1996):1–48.
   Google Scholar
• KUMAR S AND BARNETT AH: Causes of non-insulin dependent diabetes mellitus. Medicine (1997) 7:6–9.
   Google Scholar
• WILLIAMS G: Management of NIDDM. Lancet (1994) 343:95–100.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: UKPDS 16: Overview of 6 years therapy of Type 2 diabetes- a progressive disease. Diabetes (1995) 44:1249–1258.
   PubMed Web of Science ®Google Scholar
• GERICH JE: Oral hypoglycaemic agents. N Engl. J Med.(1989) 321: 1231–1245.
   PubMed Web of Science ®Google Scholar
• DAY C: Thiazolidinediones: a new class of antidiabeticdrugs. Diabel Med. 16:162–179.
   Google Scholar
• STEVENSON RW, GIBBS EM, KRENTER DK et al: Thethiazolidinedione drug series. In: The DiabetesAnnual 9. Marshall SM, Home PD, Rizza RA. Elsevier Science, Amsterday (1995):175–191.
   Google Scholar
• HOFMANN CA, COLCA JR: New oral thiazolidinedioneantidiabetic agents act as insulin sensitisers. Diabetes Care (1992) 15:1075–1078.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in thetreatment of insulin resistance and Type 2 diabetes. Diabetes (1996) 45: 1661-1669.
   Google Scholar
• SPIEGELMAN BM: PPAR-7: Adipogenic regulator andthiazolidinedione receptor. Diabetes (1998) 47:507–514.
   PubMed Web of Science ®Google Scholar
• KLETZIEN R, CLARKE S, ULRICH R: Enhancement ofadipocyte differentiation by an insulin sensitising agent. Mot. Pharmacol. (1992) 41:393–398.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, WHITCOMB RW: Hepatic dysfunction associated with troglitazone. N Engl. J Med. (1998) 338:908–909.
   PubMed Web of Science ®Google Scholar
• YOUNG PW, CAWTHORNE MA, COYLE PK et al: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitiser, enhances insulin action in white adipocytes. Diabetes (1995) 44:1087–1092.
   PubMed Web of Science ®Google Scholar
• SMITHKLINE BEECHAM: Avandia: Draft product charac-teristics (2000).
   Google Scholar
• NOLAN JJ, JONES NP, PATWARDHAN R, DEACON LF: Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabel Med. 17:287–294.
   Google Scholar
• LEBOVITZ HE, PATEL J, DOLE J et al.: Rosiglitazone (BRE49653) monotherapy significantly improves glycemic control in Type 2 diabetic patients. Diabetologica (1998) 41:1-V A2138.
   Google Scholar
• GRUNBERGER G.,WESTON WM, PATVVHARDAN R et al:Rosiglitazone once or twice daily improves glycemic control in patients with Type 2 diabetes. Diabetes (1999) 48:A102. Abstract 0439.
   Google Scholar
• WOLFENBUTTEL BIR, GOMIST R, SQUATRITO S et al: Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. DiabeL Med. (2000) 17:40–47.
   PubMed Web of Science ®Google Scholar
• FONSECA V, BISWAS N, SALZMAN A: Once daily rosigli-tazone in combination with metformin effectively reduces hyperglycaemia in patients with Type 2 diabetes. Diabetes (1999) 48:0431.
   Web of Science ®Google Scholar
• PATEL J, WESTON WM, HEMYARI P: Rosiglitazone decreases insulin resistance and improves 13-cell function in patients with Type 2 diabetes mellitus. (SmithKline Beecham, data on file, quoted in: Barman Balfour J, Plosker GE Rosiglitazone). Drugs (1999) 57:921–930.
   Google Scholar
• SUGIYAMA Y, SHIMURA Y, IKEDA H: Effects of pioglita-zone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arz Forsch/Drug Res. (1990) 40:436–440.
   PubMed Web of Science ®Google Scholar
• IKEDA H, TAKETOMI S, SUGIYAMA Y et al: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arz-Foisch/Drug Res. (1990) 40:156–162.
   PubMed Web of Science ®Google Scholar
• CRIJNS-KORTBOYER J, ECKLAND D: Pioglitazone has low potential for drug interactions (abstract). Diabetologia (1999) 42 (Suppl. 1):A228.
   Google Scholar
• YAMAZAKI H, SUZUKI M, TANE K et al: In vitro inhibi-tory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglita-zone. Xenobiotica (2000) 30(0:61–70.
   PubMedGoogle Scholar
• SCHNEIDER R, LESSEM J, LEKICH R: Pioglitazone is effective in the treatment of patients with Type 2 diabetes (abstract). Diabetes (1999) 48 (Suppl. 1):A109.
   Google Scholar
• MATHISEN A, GEERLOF G, HOUSER V: The effects ofpioglitazone on glucose control and lipid profile in patients with Type 2 diabetes (abstract). Diabetes (1999) 48 (Suppl. 0:A102–103.
   Google Scholar
• KANEKO T, BABA S, TOYOTA T et al: Clinical evaluationof an insulin resistance improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus on diet therapy alone - a placebo-controlled double-blind clinical study. Rinsho to Kenkyu (1997) 74 (6):1491–1514.
   Google Scholar
• KING AB: A comparison in a clinical setting of theefficacy and side effects of three thiazolidinediones. Diabetes Care (2000) 4:557.
   Google Scholar
• EGAN J, RUBIN C, MATHISEN A: Combination therapywith pioglitazone and metformin in patients with Type 2 diabetes. ADA Annual Meeting. San Antonio, USA (June 2000). Abstract 0504.
   Google Scholar
• EGAN J, RUBIN C, MATHISEN A: Adding pioglitazone tometformin therapy improves the lipid profile in patients with Type 2 diabetes. ADA Annual Meeting. San Antonio (June 2000). Abstract 0459.
   Google Scholar
• SCHNEIDER R, EGAN J, HOUSER V: Combination therapy with pioglitazone and sulfonylurea in patients with Type 2 diabetes (abstract). Diabetes (1999) 48 (Suppl. 1):A 106.
   Google Scholar
• CAREY RA, LIU Y: Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy p h arm acokin etics. Diabetes (2000) 49(100) (Suppl. 1). Abstract 405–P
   Google Scholar
• TAKEDA PHARMACEUTICALS AMERICA, INC.: Actos (pioglitazone HCL): Brief summary of prescribing information. Lincolnshire, IL, USA (1999).
   Google Scholar